375 related articles for article (PubMed ID: 34888848)
61. Transcriptomic signature associated with carcinogenesis and aggressiveness of papillary thyroid carcinoma.
Teng H; Mao F; Liang J; Xue M; Wei W; Li X; Zhang K; Feng D; Liu B; Sun Z
Theranostics; 2018; 8(16):4345-4358. PubMed ID: 30214625
[TBL] [Abstract][Full Text] [Related]
62. Comprehensive gene expression analysis for exploring the association between glucose metabolism and differentiation of thyroid cancer.
Suh HY; Choi H; Paeng JC; Cheon GJ; Chung JK; Kang KW
BMC Cancer; 2019 Dec; 19(1):1260. PubMed ID: 31888560
[TBL] [Abstract][Full Text] [Related]
63. The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer.
Colombo C; Minna E; Gargiuli C; Muzza M; Dugo M; De Cecco L; Pogliaghi G; Tosi D; Bulfamante G; Greco A; Fugazzola L; Borrello MG
J Exp Clin Cancer Res; 2020 Nov; 39(1):245. PubMed ID: 33198784
[TBL] [Abstract][Full Text] [Related]
64. A novel lncRNA-miRNA-mRNA network analysis identified the hub lncRNA RP11-159F24.1 in the pathogenesis of papillary thyroid cancer.
Jiang W; Zhan H; Jiao Y; Li S; Gao W
Cancer Med; 2018 Dec; 7(12):6290-6298. PubMed ID: 30474931
[TBL] [Abstract][Full Text] [Related]
65. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
[TBL] [Abstract][Full Text] [Related]
66. MicroRNAs miR-146-5p and let-7f as prognostic tools for aggressive papillary thyroid carcinoma: a case report.
Geraldo MV; Fuziwara CS; Friguglieti CU; Costa RB; Kulcsar MA; Yamashita AS; Kimura ET
Arq Bras Endocrinol Metabol; 2012 Nov; 56(8):552-7. PubMed ID: 23295297
[TBL] [Abstract][Full Text] [Related]
67. Down-regulation of DANCR acts as a potential biomarker for papillary thyroid cancer diagnosis.
Zhang K; Lv J; Peng X; Liu J; Li C; Li J; Yin N; Li H; Li Z
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30910839
[TBL] [Abstract][Full Text] [Related]
68. Analysis of the key ligand receptor CADM1_CADM1 in the regulation of thyroid cancer based on scRNA-seq and bulk RNA-seq data.
He H; Cong S; Wang Y; Ji Q; Liu W; Qu N
Front Endocrinol (Lausanne); 2022; 13():969914. PubMed ID: 36523593
[TBL] [Abstract][Full Text] [Related]
69. Potential role of LPAR5 gene in prognosis and immunity of thyroid papillary carcinoma and pan-cancer.
Zhang B; Zhang L; Qi P; Pang R; Wang Z; Liu X; Shi Q; Zhang Q
Sci Rep; 2023 Apr; 13(1):5850. PubMed ID: 37037831
[TBL] [Abstract][Full Text] [Related]
70. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
71. Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.
Genpeng L; Jianyong L; Jiaying Y; Ke J; Zhihui L; Rixiang G; Lihan Z; Jingqiang Z
Medicine (Baltimore); 2018 Feb; 97(5):e9619. PubMed ID: 29384841
[TBL] [Abstract][Full Text] [Related]
72. Impact of the Tumor Microenvironment on the Gene Expression Profile in Papillary Thyroid Cancer.
Oczko-Wojciechowska M; Pfeifer A; Jarzab M; Swierniak M; Rusinek D; Tyszkiewicz T; Kowalska M; Chmielik E; Zembala-Nozynska E; Czarniecka A; Jarzab B; Krajewska J
Pathobiology; 2020; 87(2):143-154. PubMed ID: 32320975
[TBL] [Abstract][Full Text] [Related]
73. IGFBP3 as an indicator of lymph node metastasis and unfavorable prognosis for papillary thyroid carcinoma.
Huang Y; Chang A; Zhou W; Zhao H; Zhuo X
Clin Exp Med; 2020 Nov; 20(4):515-525. PubMed ID: 32596748
[TBL] [Abstract][Full Text] [Related]
74. MicroRNAs and Lymph Node Metastasis in Papillary Thyroid Cancers.
Mutalib NS; Yusof AM; Mokhtar NM; Harun R; Muhammad R; Jamal R
Asian Pac J Cancer Prev; 2016; 17(1):25-35. PubMed ID: 26838219
[TBL] [Abstract][Full Text] [Related]
75. Functional loss of tumor suppressor genes detected by loss of heterozygosity, but not driver mutations, predicts aggressive lymph node status in papillary thyroid carcinoma.
Finkelstein S; Timmaraju VA; Samankan S; O'Malley Q; Kapustin D; Spaulding S; Xing M; Matloob A; Beute J; Seo G; Saturno M; Greenberg L; Wein L; Gonzalez-Velazquez C; Doyle S; Levine J; Urken M; Brandwein-Weber M
Pathol Res Pract; 2023 Nov; 251():154842. PubMed ID: 37890270
[TBL] [Abstract][Full Text] [Related]
76. Three-dimensional genome landscape comprehensively reveals patterns of spatial gene regulation in papillary and anaplastic thyroid cancers: a study using representative cell lines for each cancer type.
Zhang L; Xu M; Zhang W; Zhu C; Cui Z; Fu H; Ma Y; Huang S; Cui J; Liang S; Huang L; Wang H
Cell Mol Biol Lett; 2023 Jan; 28(1):1. PubMed ID: 36609218
[TBL] [Abstract][Full Text] [Related]
77. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma.
Zhang XJ; Su YR; Liu D; Xu DB; Zeng MS; Chen WK
J Surg Res; 2014 Dec; 192(2):487-93. PubMed ID: 24974154
[TBL] [Abstract][Full Text] [Related]
78. Comprehensive transcriptomic analysis of papillary thyroid cancer: potential biomarkers associated with tumor progression.
Hosseinkhan N; Honardoost M; Blighe K; Moore CBT; Khamseh ME
J Endocrinol Invest; 2020 Jul; 43(7):911-923. PubMed ID: 31965517
[TBL] [Abstract][Full Text] [Related]
79. Construction of a Signature Model to Predict the Radioactive Iodine Response of Papillary Thyroid Cancer.
Liu L; Shi Y; Lai Q; Huang Y; Jiang X; Liu Q; Huang Y; Xia Y; Xu D; Jiang Z; Tu W
Front Endocrinol (Lausanne); 2022; 13():865909. PubMed ID: 35634509
[TBL] [Abstract][Full Text] [Related]
80. Inflammatory Components of the Thyroid Cancer Microenvironment: An Avenue for Identification of Novel Biomarkers.
Jarboe T; Tuli NY; Chakraborty S; Maniyar RR; DeSouza N; Xiu-Min Li ; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():1-31. PubMed ID: 34888842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
